REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Acyclic Nitrogen Double Bonded To Acyclic Nitrogen, Acyclic Nitrogen Triple Bonded To Acyclic Nitrogen Or Azide Doai Acyclic Nitrogen Double Bonded To Acyclic Nitrogen, Acyclic Nitrogen Triple Bonded To Acyclic Nitrogen Or Azide DoaiAcyclic Nitrogen Double Bonded To Acyclic Nitrogen, Acyclic Nitrogen Triple Bonded To Acyclic Nitrogen Or Azide Doai patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010497 - Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine The invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient which is a P2X7 receptor antagonist, and a second active ingredient which is 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid (sulfasalazine) or a pharmaceutically acceptable derivative thereof, for use in the treatment of inflammatory disorders. ... 01/04/07 - 20070004684 - Alpha-carbolines as cdk-1 inhibitors R2 to R5 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties. ... 11/23/06 - 20060264408 - Sod minic multifunctional compounds for treating inflammatory bowel disease The present invention relates to multifunctional compounds comprising an anti-inflammatory or immunomodulatory component, and at least one SOD mimic component capable of reacting with reactive oxygen species, and to their use in treating inflammatory bowel disease comprising ulcerative colitis and Crohn's disease. Preferred anti-inflammatory or immunomodulatory components comprise derivatives of ... 11/16/06 - 20060258629 - Photodynamic therapy for ocular neovascularization Method, apparatuses and systems are provided for the photodynamic treatment of feeder vessels associated with aberrant choroidal neovasculature. ... 08/31/06 - 20060194771 - Azobenzene derivative compound, particle and method of fabricating the same (wherein R1 denotes a hydrogen atom, halogen atom, cyano group, amino group, ester group, nitro group, alkyl group, alkoxyl group, cycloalkyl group, or heterocyclic group; m and n each independently denote an integer ranging from 1 to 6; R2 to R9 each independently denote a hydrogen atom or alkyl group; ... 08/17/06 - 20060183718 - Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, ... 07/27/06 - 20060166943 - Microbicidal pyrimidine or triazine for preventing sexual hiv transmission A present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans. ... 06/08/06 - 20060122156 - Heteroaryl compounds their compositions and methods of use thereof. The compounds (and compositions) are useful in modulating IL-12 production and processes mediated by IL-12. ... 03/16/06 - 20060058270 - Ruthenium anticancer complexes Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer, wherein formula (I) is: ... 02/09/06 - 20060030548 - Methods of using ryanodine antagonists in treating neural injury The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a ryanodine antagonist, e.g. dantrolene, to inhibit or prevent nerve cell injury or death. ... 01/05/06 - 20060003970 - Novel combi-molecules having egfr and dna targeting properties A series of new chemical agents that demonstrate anti-tumor activity are described. The new chemical agents combine two major mechanisms of anti-tumor action. In an embodiment, the agents are capable of both inhibiting EGFR and damaging DNA while also, upon degradation, degrading to an inhibitor of EGFR and to an ... 12/08/05 - 20050272709 - Immugenic compositions and diagnostic and therapeutic uses thereof Pharmaceutical compositions and compounds are provided. The compounds of the invention deomonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical ... 12/01/05 - 20050267078 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma ... 11/24/05 - 20050261255 - Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from ... 11/03/05 - 20050245491 - Tetracycline derivatives and methods of use thereof A treatment for inhibiting microbial or tumor growth is disclosed, which comprises adding to a subject in need of treatment an effective amount of one or more tetracycline derivatives. ... 09/22/05 - 20050209201 - Method and composition for suppression of inflammation The present invention provides a method and composition which ameliorate inflammation, and suppress its onset, by allowing ATP receptor antagonists to act on ATP receptors of cells to block them and thereby inhibit the release of inflammatory cytokines, particularly interleukin-6 (IL-6) and/or interleukin-8 (IL-8), by the cells. ... 08/11/05 - 20050176689 - Compounds having selective cytochrome p450rai-1 or selective cytochrome p450rai-2 inhibitory activity and methods of obtaining the same Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme. ... 08/04/05 - 20050171067 - Methods of treating disorders with group i mglur antagonists mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome. ... 08/04/05 - 20050171066 - Vivo use of glutathione s-transferase activated nitric oxide donors The present invention provides for a method of simultaneously treating both cancer and the Multidrug Resistance Phenotype via inhibition of cellular thiols, such as Glutathione S-Transferase (GST). This enzyme is overproduced in leukemia and solid tumor cells and is one of the main pathways involved in the Multidrug Resistance phenotype. ... 07/14/05 - 20050153941 - Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line The object of the present invention is to provide a differentiation inhibiting agent which allows culture of a stem cell or an embryonic stem cell in an undifferentiated state without use of any feeder cell, a method for culturing using the same, a cell culture liquid using the same, and ... 07/07/05 - 20050148550 - Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine compounds Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds, processes for their preparation, medicaments and pharmaceutical compositions containing them, and their use in treatment methods and in the preparation of analgesics, in the preparation of a local anaesthetic, an antiarrhythmic, an antiemetic, a nootropic agent and/or a medicament for the treatment and/or prophylaxis of ... ### FreshPatents.com Support |